Canadian Medical Isotope Ecosystem

How are isotopes like Iodine-131 used in the treatment? Iodine-131 is a key treatment for thyroid cancer, effectively destroying cancerous cells while sparing surrounding healthy tissue.

Project Spotlight: ProteinQure (Ontario) Project: AI-driven optimization of a companion radiodiagnostic for a novel breast cancer therapeutic. Triple negative breast cancer (TNBC) presents significant treatment challenges, characterized by a 12% five-year survival rate, limited targeted therapy options, and invasive tests for treatment planning. Sortilin (SORT1), a cell surface and internalizing receptor overexpressed in various cancers, shows promise as a target for delivering high-potency, cytotoxic payloads or isotopes, aimed at maximizing toxicity towards cancer cells whilst minimizing it towards normal cells. ProteinQure has a development candidate (PQ-203) for TNBC, currently in Investigational New Drug (IND) enabling studies. Our modular peptide-drug conjugate comprises a cytotoxic payload conjugated to a peptide targeting SORT1. Building on this, ProteinQure has initiated the development of a companion radiodiagnostic as part of the CMIEDF. Our project will optimize the peptide that could form the basis for a radiodiagnostic (and eventually a radiotherapeutic). 

🚨 Reminder: CMIE Development Fund's Second Call for Proposals - Deadline Approaching! 🚨 The submission deadline for the CMIE Development Fund's Second Call for Proposal is just over a month away: August 20, 2024, at 11:59pm PST. Submit a brief, non-confidential PowerPoint presentation using the template provided in the link below. Don't miss this opportunity to secure funding for your medical isotope project! To learn more, please visit our website: https://lnkd.in/e4iu8su6   #FundingOpportunity #Innovation #CMIEDF

#IsotopeFact Cobalt-60 is used for Gamma Knife therapies to treat brain tumors. Multiple tiny beams of radiation are targeted on a tumor with extreme accuracy. Bruce Power and Nordion have recently successfully completed the 2024 Cobalt-60 harvest. Thank you to this team for helping to supply a valuable cancer treatment.

Project Spotlight: Synergy Oncology (Nova Scotia) Synergy Spheres, a groundbreaking development in Selective Internal Radiation Therapy (SIRT), represent a significant leap forward in cancer treatment. These third-generation microspheres promise to redefine personalized cancer care, especially for extra-hepatic cancers.   Featuring enhanced physical integrity and precise imaging capabilities, Synergy Spheres offer unparalleled delivery accuracy and real-time monitoring. Their adaptability to carry various therapeutic radionuclides allows for tailored treatment plans, optimizing outcomes across different cancer types. Backed by CMIEDF funding, Synergy Oncology aims to refine and validate the product through rigorous laboratory testing, paving the way for clinical trials in 2025. This advancement holds the potential to revolutionize cancer treatment, offering hope to patients worldwide.

#Radiologists select isotopes that quickly exit the body through excretion or naturally decay to non-radioactive isotopes. This is controlled by the half-life of the isotope.

#Throwback to the 2024 Canadian Radiotheranostics Leaders’ Summit. Thank you to our event partners, the Canadian Nuclear Isotope Council and University Health Network for helping organize and facilitate many important conversations in our field. We look forward to seeing our sponsors, speakers, and attendees next year as we continue to make advancements!

#IsotopeFact Lutetium-177 is used in peptide receptor radionuclide therapy (PRRT) to treat neuroendocrine tumors, offering a targeted approach with promising results. 

Last year, the formal announcement was delivered by Pam Damoff and François-Philippe Champagne, Minister of Innovation, Science and Industry, for the federal government to provide up to $35 million to support the development, production, advancement, and distribution of medical isotopes used in the fight against cancer and in diagnostic imaging. We thank the government for your continued support of the CMIE. Learn more here: https://lnkd.in/g7id5h2s

📢Exciting Announcement! Second Call for Proposals Now Open! The CMIE is pleased to share that our second call for proposals is officially open! We are offering up to $500k in matched funds to Canadian innovators, researchers, and SMEs to support the development of groundbreaking research in the medical isotope sector. 🔍Important Information: • Submission Deadline: August 20, 2024 (11:59 PM PST) • Focus Areas: Innovative medical isotope technologies (radiopharmaceutical development, novel isotope production methods, etc.) We look forward to seeing your innovative ideas and projects. Together, let's shape the future of the Canadian Medical Isotope Ecosystem! For more details, visit https://lnkd.in/e4iu8su6.